Cargando…
The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System
The field of gene editing is undergoing unprecedented growth. The first ex vivo human clinical trial in China started in 2016, more than 1000 US patents have been filed, and there is exponential growth in publications. The ability to edit genes with high fidelity is promising for the development of...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485762/ https://www.ncbi.nlm.nih.gov/pubmed/28918056 http://dx.doi.org/10.1016/j.omtn.2017.06.006 |
_version_ | 1783246136246534144 |
---|---|
author | Jubair, Luqman McMillan, Nigel A.J. |
author_facet | Jubair, Luqman McMillan, Nigel A.J. |
author_sort | Jubair, Luqman |
collection | PubMed |
description | The field of gene editing is undergoing unprecedented growth. The first ex vivo human clinical trial in China started in 2016, more than 1000 US patents have been filed, and there is exponential growth in publications. The ability to edit genes with high fidelity is promising for the development of new treatments for a range of diseases, particularly inherited conditions, infectious diseases, and cancers. For cancer, a major issue is the identification of driver mutations and oncogenes to target for therapeutic effect, and this requires the development of robust models with which to prove their efficacy. The challenge is that there is rarely a single critical gene. However, virally driven cancers, in which cells are addicted to the expression of a single viral oncogene in some cases, may serve as model systems for CRISPR/Cas therapies, as they did for RNAi. These models and systems offer an excellent opportunity to test both preclinical models and clinical conditions to examine the effectiveness of gene editing, and here we review the options and offer a way forward. |
format | Online Article Text |
id | pubmed-5485762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-54857622017-07-10 The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System Jubair, Luqman McMillan, Nigel A.J. Mol Ther Nucleic Acids Review The field of gene editing is undergoing unprecedented growth. The first ex vivo human clinical trial in China started in 2016, more than 1000 US patents have been filed, and there is exponential growth in publications. The ability to edit genes with high fidelity is promising for the development of new treatments for a range of diseases, particularly inherited conditions, infectious diseases, and cancers. For cancer, a major issue is the identification of driver mutations and oncogenes to target for therapeutic effect, and this requires the development of robust models with which to prove their efficacy. The challenge is that there is rarely a single critical gene. However, virally driven cancers, in which cells are addicted to the expression of a single viral oncogene in some cases, may serve as model systems for CRISPR/Cas therapies, as they did for RNAi. These models and systems offer an excellent opportunity to test both preclinical models and clinical conditions to examine the effectiveness of gene editing, and here we review the options and offer a way forward. American Society of Gene & Cell Therapy 2017-06-12 /pmc/articles/PMC5485762/ /pubmed/28918056 http://dx.doi.org/10.1016/j.omtn.2017.06.006 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Jubair, Luqman McMillan, Nigel A.J. The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System |
title | The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System |
title_full | The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System |
title_fullStr | The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System |
title_full_unstemmed | The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System |
title_short | The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System |
title_sort | therapeutic potential of crispr/cas9 systems in oncogene-addicted cancer types: virally driven cancers as a model system |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485762/ https://www.ncbi.nlm.nih.gov/pubmed/28918056 http://dx.doi.org/10.1016/j.omtn.2017.06.006 |
work_keys_str_mv | AT jubairluqman thetherapeuticpotentialofcrisprcas9systemsinoncogeneaddictedcancertypesvirallydrivencancersasamodelsystem AT mcmillannigelaj thetherapeuticpotentialofcrisprcas9systemsinoncogeneaddictedcancertypesvirallydrivencancersasamodelsystem AT jubairluqman therapeuticpotentialofcrisprcas9systemsinoncogeneaddictedcancertypesvirallydrivencancersasamodelsystem AT mcmillannigelaj therapeuticpotentialofcrisprcas9systemsinoncogeneaddictedcancertypesvirallydrivencancersasamodelsystem |